Ralph Torgler
19.01.2021
Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland
Mullhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly 2021; 151:w20399.
19.01.2021Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland
19.01.2021Swiss Med Wkly 2021; 151:w20399
Mullhaupt Beat, Semela David, Ruckstuhl Lisa, Magenta Lorenzo, Clerc Olivier, Torgler Ralph, Negro Francesco, Semmo Nasser
Weiter
04.11.2020
A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study
Semmo N, Mullhaupt B, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Semela D. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. PloS one 2020; 15:e0241267.
04.11.2020A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study
04.11.2020PloS one 2020; 15:e0241267
Semmo Nasser, Mullhaupt Beat, Ruckstuhl Lisa, Magenta Lorenzo, Clerc Olivier, Torgler Ralph, Semela David
Weiter